Phase II Results For Low-Dose Oral Immune Tolerance Therapy (ARG201) In Systemic Scleroderma Published

arGentis Pharmaceuticals, LLC announced that the Phase II results using highly purified type 1 bovine collagen orally (now known as ARG201) in the treatment of diffuse cutaneous systemic sclerosis (scleroderma - SSc) have been published in the June issue of Arthritis & Rheumatism, a major peer-reviewed rheumatology research journal.

More: continued here

Filed under: Arthritis on July 4th, 2008